These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3104347)

  • 1. Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide.
    Wagner T; Zink M; Schwieder G
    J Cancer Res Clin Oncol; 1987; 113(2):160-5. PubMed ID: 3104347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracavitary chemotherapy with activated cyclophosphamides and simultaneous systemic detoxification with protector thiols in Sarcoma 180 ascites tumor.
    Wagner T; Mittendorff F; Walter E
    Cancer Res; 1986 May; 46(5):2214-9. PubMed ID: 3697966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the uroprotector sodium 2-mercaptoethane sulfonate (Mesna) on the proliferation of the bladder urothelium in the rat after administration of cyclophosphamide.
    Kunze E; Köhnecke B; Engelhardt W; Steinröder H; Brock N; Pohl J
    Urol Int; 1984; 39(2):61-7. PubMed ID: 6426112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of Mesna (2-mercaptoethane sulfonate) with the mutagenicity of cyclophosphamide in vitro and in vivo.
    Lähdetie J; Räty R; Sorsa M
    Mutat Res; 1990 Sep; 245(1):27-32. PubMed ID: 2118231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the toxicity of cyclophosphamide in combination with mesna in vitro and in vivo.
    Millar BC; Millar JL; Clutterbuck R; Jinks S
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():63-71. PubMed ID: 6414698
    [No Abstract]   [Full Text] [Related]  

  • 6. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
    Brock N; Pohl J; Stekar J
    J Cancer Res Clin Oncol; 1981; 100(3):311-20. PubMed ID: 6792207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intracavitary chemotherapy of S 180 ascites sarcoma in mice with 4-(S-ethanol)-sulfido-cyclophosphamide in combination with protector thiols].
    Voelcker G; Jaschke A; Wrabetz E; Hohorst HJ
    Arzneimittelforschung; 1984; 34(10):1291-8. PubMed ID: 6440565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of sodium-2-mercaptoethanesulfonate on the gastrointestinal toxicity and lethality of cis-diamminedichloroplatinum.
    Allan SG; Smyth JF; Hay FG; Leonard RC; Wolf CR
    Cancer Res; 1986 Jul; 46(7):3569-73. PubMed ID: 3085925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium 2-mercaptoethane sulfonate protection against cyclophosphamide-induced teratogenicity in rats.
    Slott VL; Hales BF
    Toxicol Appl Pharmacol; 1986 Jan; 82(1):80-6. PubMed ID: 3080822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro/in vivo effects of Mesna on the genotoxicity and toxicity of cyclophosphamide--a study aimed at clarifying the mechanism of Mesna's anticarcinogenic activity.
    Pool BL; Bos RP; Niemeyer U; Theuws JL; Schmähl D
    Toxicol Lett; 1988 Apr; 41(1):49-56. PubMed ID: 3128896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).
    Brock N; Pohl J; Stekar J; Scheef W
    Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1377-87. PubMed ID: 6819957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of reduced glutathione with 2-mercaptoethane sulfonate to prevent cyclophosphamide-induced urotoxicity.
    Cavalletti E; Tofanetti O; Zunino F
    Cancer Lett; 1986 Jul; 32(1):1-6. PubMed ID: 3091245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
    Brock N; Pohl J
    IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of cytogenetic damage by 2-mercaptoethanesulfonate in cultured human lymphocytes exposed to cyclophosphamide and its reactive metabolites.
    Wilmer JL; Erexson GL; Kligerman AD
    Cancer Res; 1986 Jan; 46(1):203-10. PubMed ID: 3079586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
    Brock N; Stekar J
    Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice.
    Roberts JD; Hacker MP; Newman RA; McCormack JJ; Krakoff IH
    Invest New Drugs; 1984; 2(2):215-20. PubMed ID: 6469517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on hemotoxicity of cyclophosphamide, doxorubicin and cis-diamminodichloroplatinum combined with sodium-2-mercaptoethane sulfonate.
    Lerza R; Bogliolo G; Mencoboni M; Saviane A; Pannacciulli I
    Tumori; 1988 Jun; 74(3):333-7. PubMed ID: 3135644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of mesna for regional detoxification.
    Brock N; Pohl J
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():33-43. PubMed ID: 6414694
    [No Abstract]   [Full Text] [Related]  

  • 19. Combinations of mesna with cyclophosphamide or adriamycin in the treatment of mice with tumors.
    Bernacki RJ; Bansal SK; Gurtoo HL
    Cancer Res; 1987 Feb; 47(3):799-802. PubMed ID: 3100025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Autoradiographic studies on the protective effect of mesna in the urinary bladder mucosa of the rat during administration of cyclophosphamide (preliminary communication)].
    Kunze E; Köhnecke B; Engelhardt W; Brock N; Pohl J
    Arzneimittelforschung; 1983; 33(6):853-4. PubMed ID: 6412725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.